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HemolysisThe interaction between a peptide sequence fromGBvirus C E1protein (E1P8) and its structural analogs (E1P8-12),
(E1P8-13), and (E1P8-21) with anionic lipid membranes (POPG vesicles and POPG, DPPG or DPPC/DPPG (2:1)
monolayers) and their association with HIV-1 fusion peptide (HIV-1 FP) inhibition at the membrane level
were studied using biophysical methods. All peptides showed surface activity but leakage experiments in vesi-
cles as well as insertion kinetics in monolayers and lipid/peptide miscibility indicated a low level of interaction:
neither E1P8 nor its analogs induced the release of vesicular content and the exclusion pressure values (πe)
were clearly lower than the biological membrane pressure (24–30 mN m−1) and the HIV-1 FP (35 mN m−1).
Miscibility was elucidated in terms of the additivity rule and excess free energy of mixing (GE). E1P8, E1P8-12
and E1P8-21 (but not E1P8-13) induced expansion of the POPG monolayer. The mixing process is not thermo-
dynamically favored as the positive GE values indicate. To determine how E1 peptides interfere in the action of
HIV-1 FP at the membrane level, mixed monolayers of HIV-1 FP/E1 peptides (2:1) and POPG were obtained.
E1P8 and its derivative E1P8-21 showed the greatest HIV-1 FP inhibition. The LC-LE phase lipid behavior was
morphologically examined via ﬂuorescence microscopy (FM) and atomic force microscopy (AFM). Images
revealed that the E1 peptidesmodify HIV-1 FP–lipid interaction. This fact may be attributed to a peptide/peptide
interaction as indicated by AFM results. Finally, hemolysis assay demonstrated that E1 peptides inhibit
HIV-1 FP activity.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Recent years have seen the publication of numerous studies in
which co-infection with GB virus C (GBV-C) and HIV-1 has been associ-
ated with slower progression of the illness and a higher survival rate of
patients once AIDS has developed [1–3]. These two viruses share
transmission routes and thus co-infection is common [4].
Several studies have been published to propose different models of
interaction between GBV-C and HIV-1 virus [5]. One of the proposed
mechanisms by which GBV-C modulates HIV-1 infection and AIDS
progression involves inhibiting HIV-1 replication in vitro by GBV-C
proteins [6–9]. Based on single cycle replication studies, E2 and NS5A
viral proteins inhibit HIV-1 at least in part at the HIV-1 entry step. The
GBV-C E2 protein directly inhibits HIV-1 pseudovirus entry, and pep-
tides derived from the E2 protein interfere with HIV-1 cellular binding
and fusion, independent of the viral effect on CD4 cell homeostasis [6,7].
In contrast, NS5A protein expression down regulates CXCR4 surface34 93 403 59 87.expression and induces the release of the CXCR4 ligand (SDF-1) in
CD4+ T cells [8,9]. GBV-C NS5A protein also decreases CD4 surface
expression via a reduction in steady state CD4 mRNA levels [10].
In our hands, certain 18-mer peptide sequences of the E2 envelope
protein of the GBV-C notably decrease cellular membrane fusion and
interfere with HIV-1 infectivity, highlighting their potential utility in
future anti-HIV-1 therapies [11]. Furthermore, synthetic peptides
derived from GBV-C E1 protein also inhibit HIV-1 entry and appear to
interact with HIV-1 FP [12–17].
Based on these ﬁndings, the sequence E1 (22–39) of GBV-C protein
(E1P8) was selected [14,16,17] in order to better analyze its interaction
with HIV-1 FP. We studied the inﬂuence of each amino acid residue on
the primary structure and the total net charge of the peptide. Firstly,
we replaced each amino acid in the sequence with Ala and replaced
charged residues with neutral amino acids [18]. Then the E1 peptide
analogs were evaluated with regard to their capacity to inhibit the
destabilization process of POPG unilamellar lipid vesicles induced by
HIV-1 FP [18]. Three derivatives of GBV-C E1P8 (E1P8-12, E1P8-13 and
E1P8-21) were selected on the basis of a higher effect relative to the
parent peptide E1P8 in terms of decreasing the leakage of vesicular
content induced by HIV-1 FP [18].
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as viral infection or neurotransmission for instance, take place through
the membrane. The membrane models are used frequently to under-
stand these processes. It is known that HIV-1 FP interacts more with
negatively charged lipids than zwitterionic lipids [19]. In this work,
to mimetize the negative charge feature, anionic phospholipids POPG
(1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) and DPPG
(1,2-dipalmitoyl-sn-glycero-3-phophoglycerol) and a mixture of DPPC
(1,2-dipalmitoyl-sn-glycero-3-phosphocholine) and DPPG (2:1) were
chosen. As model membranes, POPG unilamelar vesicles were used for
leakage studies; POPG monolayers to characterize thermodynamically
peptide–lipid interactions and the peptide insertion in the lipid mono-
layer; DPPG to obtain Langmuir–Blodgett ﬁlms for ﬂuorescencemicros-
copy (FM) in order to analyze the effect on lipid phase transition. To
realize the lipid–peptide and peptide–peptide interaction a molecular
level, a mixture of DPPC/DPPG (2:1) that resembles better the negative
charge ratio in biological membranes, was used to obtain Langmuir–
Blodgett ﬁlms on mica substrate for AFM imaging studies. Finally, we
performed hemolysis assays with rabbit cells in order to conﬁrm
peptides activity in vivo.2. Materials and methods
2.1. Materials
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol)
(POPG), 1-palmitoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]
hexanoyl}-sn-glycero-3-phosphocoline (NBD-PC), 1,2-dipalmitoyl-sn-
glycero-3-phophoglycerol (DPPG) and 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) were purchased from Avanti Polar Lipids.
Chloroform and methanol were purchased from Merck. Double
distilled anddeionizedwaterwas used (18.2MΩcm, pH5.8) (MilliQ sys-
tem, Millipore). Hepes (Sigma-Aldrich) 5 mM and NaCl (Carlo Erba)
20 mM were used to make a buffer solution, pH 7.4. PBS buffer 0.1 M
was prepared with 120 mM NaCl, 2.7 mM KCl and 10 mM Na2HPO4
(Merck).2.2. Peptide synthesis
The E1P8 peptide (APEDIGFCLEGGCLVALG) corresponding to E1
protein of GBV-C) and its derived analogs E1P8-12, E1P8-13 and
E1P8-21, were synthesized via solid-phase peptide methodology
following a 9-ﬂuorenylmethoxycarbonyl (Fmoc) strategy by means of
DIEA/HATU activation.
HIV-1 FP was synthesized in the same way but using a polyethylene
glycol-based resin, ChemMatrix, via solid phase methodology as
described previously [11].
Crude peptides were desalted using an Oasis HLB Plus cartridge
225 mg/60 μg from Waters. These cartridges contain a polymeric
water-wettable reversed phase sorbent.
The ﬁnal characterization of synthetic peptides was carried out via
analytical HPLC and electrospray mass spectrometry.2.3. Surface activity of peptides
The experiments were carried out on a NIMA Langmuir Balance
(Coventry, UK) at 297 ± 1 K. Using a cylindrical PTFE trough
(19.6 cm2, 30 ml), increasing volumes of E1P8, E1P8-12, E1P8-13, and
E1P8-21 peptide solution (1 mg ml−1 in acetonitrile/H2O) were
injected below the Hepes subphase (pH 7.4) through a lateral hole.
The subphase was stirred continuously with a miniature Teﬂon-coated
spinning rod. Surface pressure, π, was monitored with an accuracy of
±0.05 mNm−1 using a platinum plate as the pressure sensor.2.4. Penetration kinetics
The kinetics of insertion of the peptides into monolayers of POPG
was measured using the same trough as for the surface activity. Lipids
from a concentrated solution (1 mg ml−1 in chloroform) were spread
at the air/water interface until the desired lipid surface pressure (πi)
was achieved. Once the lipid monolayer had equilibrated, a 0.38 μM
peptide solution was injected into the Hepes subphase through the
side hole of the trough. The subphase was magnetically stirred during
the measurements, and surface pressure changes were monitored as a
function of time until pressure remained constant. The experiment
was carried out at 297 ± 1 K.
2.5. Compression isotherms
Compression isotherms were performed at room temperature
(297 ± 1 K) in a NIMA Langmuir Teﬂon trough (surface area 690 cm2,
volume 350 ml) containing Hepes 5 mM pH 7.4. Lipids were dissolved
in chloroform (1 mg ml−1). Pure peptide monolayers (1 mg ml−1)
were formed by direct spreading from DMSO (5%)/chloroform solution
using a microsyringe. Mixed monolayers were obtained by premixing
lipid/peptides in the desired proportions, and then directly spreading
on the surface. The spreading solvent was allowed to evaporate for at
least 10 min before compression started, at a rate of 5 cm2 min−1.
2.6. Fluorescence microscopy
Surface pressure-area measurements were performed using a NIMA
Langmuir–Blodgett trough (surface area 200 cm2) equipped with a
continuous Teﬂon-ribbon barrier able to sustain maximal surface pres-
sures with no leakage, and thermostated at the desired temperature
(297 ± 1 K). The trough was set inside a custom-made closed chamber
to ensure isolation from external light.
The phospholipid DPPG (1 mM), containing 1 mol% of NBD-PC, and
its mixtures with peptides (5% with respect to phospholipid, mol/mol)
were prepared in chloroform/methanol (2:1 v/v). Monolayers were
formed by applying small drops of the spreading solution on the
water subphase. After 10 min, Langmuir–Blodgett ﬁlms were prepared
using the COVASP method [19,20]. Brieﬂy, as Wang et al. described [19],
in this method the monolayers were compressed at 25 cm2 min−1 along
the pressure-area isotherms while simultaneously being transferred
onto a Menzel-Glaser 24 mm × 60 mm cover slips at a rate of substrate
movement of 5 cm2 min−1. The entire transferred ﬁlm typically occu-
pied a length of ∼20 mm on the substrate. π-A compression isotherms
were simultaneously recorded during the transfer. This technique
permits capture of all the structural features shown by a given ﬁlm
along the whole compression isotherm in a single supported layer
(termed continuously varying surface pressure (COVASP) ﬁlms).
The transferred monolayers were observed in a Leica DM4000B
microscope (Leica Microsystems, Wetzlar, Germany) equipped with
appropriate ﬂuorescence ﬁlters to allow for the observation of NBD-PC
ﬂuorescence (maximum ﬂuorescence excitation at 480 nm and emis-
sion at 526 nm). Images of the transferred ﬁlmswere obtained at differ-
ent positions and subsequently assigned to the surface pressures
obtained during ﬁlm transfer [19].
2.7. AFM measurements
AFM intermittent contact mode images in air were obtained using a
Nanoscape IV Multimode AFM (Bruker AXS Corporation, Madison, WI)
with MSNL silicon tips with a nominal spring constant of 30 pN nm−1.
To minimize the applied force on the sample, the set point was contin-
uously adjusted during imaging. Images were acquired at 0° scan angle
at 1.5 Hzof scan rate. All imageswere processed using Bruker and Image
software.
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Fig. 1. Surface activity curve of E1P8 and its analogues peptides.
Table 1
Analysis of the adsorption isotherms of parent peptide E1P8 and its analogues E1P8-12,
E1P8-13, E1P8-21. πmax is themaximumsurface pressure achieved and K is a characteristic
constant equal to the peptide concentration that yields (1/2) πmax. Γmax is the maximum
surface excess concentration at equilibrium and A is the molecular area.
πmax (mN m−1) K (μM) Γmax (mol m−2) A (nm2 mol−1)
E1P8 22 0.45 1.53 × 10−6 1.06
E1P8-12 23 0.44 1.59 × 10−6 1.04
E1P8-13 22 0.32 1.48 × 10−6 1.12
E1P8-21 24 0.42 1.52 × 10−6 1.09
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For the leakage assay [21,22], unilamellar lipid vesicles (LUVs)
of POPG containing ﬂuorescent probes ANTS (8-aminonaphtalene-
1,3,6-trisulfonic acid) and DPX (N,N′-p-xylene-bis(pyridinium bromide)
in Hepes buffer (5mM, pH7.4)were prepared according to a previously
described protocol [23].
The peptides dissolved in DMSO were added to the suspension
0.1 mM of LUVs, and the ﬂuorescence was measured in a PTI QM4CW
spectroﬂuorimeter (at room temperature) before and after detergent
was added. The dequenching of coencapsulated ANTS and DPX ﬂuores-
cence resulting from dilution was measured to assess the leakage of
aqueous contents from vesicles. Leakage was monitored by measuring
the increase in the ANTS/DPX ﬂuorescence intensity at 520 nm, with
an excitation of 355 nm. The peptide/LUVs molar ratio was 1/3.
The percentage of leakage was calculated according to the equation:
%leakage = [(F − F0)/(F100 − F0)] × 100, in which F0 is the initial
ﬂuorescence of LUVs, F is the ﬂuorescence intensity after adding the
peptide, and F100 is the ﬂuorescence intensity after the addition of
10 μl of a 10% (v/v) Triton 100 solution (complete lysis of LUVs).
2.9. Hemolysis assay
The effect of E1P8 peptide and its analogs (E1P8-12, E1P8-13 and
E1P8-21) on red blood cell destabilization promoted by the presence
of HIV-1 FPwas determined after incubation of different concentrations
of the E1P8 peptides with diluted suspensions of cells.
Rabbit blood samples were extracted immediately before use.
Erythrocytes were centrifuged for 10 min at 1000g. The supernatant
was discarded and the pellet was washed three times with PBS. Red
blood cells were then diluted 1:10 in PBS.
Stock solutions of 2 mM HIV-1 FP and 20 mM of the parent peptide
and its analogs were prepared in DMSO. E1P8, E1P8-12, E1P8-12 and
E1P8-21 peptide aliquots ranging between 0 and 1000 μMwere distrib-
uted in tubes. Thereafter, 2 mM of HIV-1 FP solution in PBS was added,
resulting in a ﬁnal HIV-1 FP concentration of 100 μM. After 60 min at
310 K, 10% of the erythrocytes were added and incubated for another
60 min at 310 K. Each sample was prepared and analyzed in triplicate.
Thereafter, cells were pelleted for 5 min at 1000g. Supernatants were
transferred to 96-MicroWell™ Solid Plates and optical density was
measured at 405 nm. Percent hemolysis values were expressed relative
to the total hemolysis caused by the respective HIV-1 FP alone.
3. Results and discussion
3.1. Surface activity of peptides
Surface activity experiments provide information about the capacity
of a peptide to adsorb or incorporate into the air-buffered interface.
The adsorption kinetics of E1P8 and its analogs (E1P8-12, E1P8-13
and E1P8-21) was measured by injecting increasing volumes of a
concentrated peptide solution into a Hepes subphase and recording
the surface pressure achieved as a function of time at a constant area.
The experiments were carried out for more than 2 h in every case, but
after 100 min the pressure remained constant, and we considered the
equilibrium to have been reached by this time.
For each peptide studied a slight gradual adsorption of peptide was
observed at low concentrations. The higher the peptide concentration
in the subphase, the faster the incorporation and the higher the surface
pressure achieved. Fig. 1 illustrates the adsorption isotherm proﬁle for
the parent peptide and its analogs. The surface activity curve was ﬁtted
via non-linear least-squares regression analysis, revealing a rectangular
hyperbola Δπ= (cπmax)/(K + c), where c is the peptide concentration,
πmax is the maximum surface pressure achieved and K is a characteristic
constant equal to the peptide concentration that reaches half πmax. The
characteristic physicochemical parameters obtained for each peptideare shown in Table 1. K values were frequently chosen for further
penetration studies, as K corresponds to the concentration of peptide
that should be used in the bulk subphase for experiments of penetration
kinetics, being lower than the equilibrium spreading pressure of the
peptide [24,25]. In our case, a different K value was found for each pep-
tide. In the kinetics experiments, in order to compare the behavior of
peptides, we used the same concentration in each case, 0.38 μM, as it
corresponds to the value of each peptide prior to reaching the equilibri-
um spreading pressure.
Analysis of the peptide adsorption process from the subphase to the
air–water interface allows the calculation of the peptide surface excess
concentration (Γ) by applying the Gibbs adsorption equation Γ= (1/RT)
(dπ/dlnc), where R is the gas constant (8,31 J K−1 mol), T is the temper-
ature (297 ± 1 K), (dπ/dlnc) is the slope of a plot of surface pressure
achieved for each peptide concentration in front of the logarithm
of peptide concentration [13]. Using peptide maximum surface
excess concentration it is possible to calculate the molecular area
(Area = 1/NΓmax, where N is Avogadro's constant). The results are
shown in Table 1.
The shape of the adsorption isotherms of the analogs was similar to
those of the parent peptide, with parameters of the same order of
magnitude as those found for other peptide sequences [14,26–29]. The
hydrophobic proﬁle based on their primary sequence clearly induced
an increase in surface pressure at the air–water interface when they
were injected into the subphase. Their high hydrophobicity proﬁle
was conﬁrmed by the Hopp–Woods scale [30]. In this type of plot,
values lower than 0 are hydrophobic. Fig. 2 shows the Hopp–Woods
proﬁle of GBV-C E1P8 protein. The red arrows indicate the E1P8
sequence. According to previous study [14], it can be seen the hydro-
phobic character of this peptide. The analogs present the same hydro-
phobic proﬁle, and for this reason the surface activity is the same.
Consequently, the surface parameters of each peptide were similar
(Table 1), including the maximum pressure achieved by peptides
(between 22 and 24mNm−1) and the area per molecule (A) (between
1.04 and 1.12 nm2 mol−1). E1P8-13 showed lower values of constant
(K) and the surface excess concentration at equilibrium.
Fig. 2.Hoop andWoods proﬁle for GBV-CE1protein obtainedby Expasy software (http://web.expasy.org/protscale/). Red arrows show the regionwhere the E1 (22–39) peptide sequence
(E1P8) is located.
395R. Galatola et al. / Biochimica et Biophysica Acta 1848 (2015) 392–4073.2. Lipid–peptide interaction
3.2.1. Leakage of vesicular contents: ANTS/DPX assay
The sequence E1P8 of the GBV protein and its derivative sequences
E1P8-12, E1P8-13 and E1P8-21 were evaluated with regard to their ca-
pacity to induce the destabilization of lipid vesicles of POPG. Thus, the
effect of the peptides on the release of the encapsulated ﬂuorophores
ANTS/DPX was monitored by dequenching of the ANTS. The peptides
were dissolved in DMSO before addition to the liposome suspension,
after which the emission of the ANTS probe was recorded at 520 nm.
The trials were performed in a PTI QM4CW spectroﬂuorimeter, in
96-well plates. The ﬂuorescence assay was carried out in triplicate and
repeated twice on different days to analyze intra- and inter-assay ﬂuo-
rescence variations. HIV-1 FP was used as a control peptide in this
assay. HIV-1 FP interacts with negatively charged phospholipids and
induces leakage from large unilamellar phospholipids of POPG [11,31].
Fig. 3 shows the percentage of leakage of LUVs induced by HIV-1 FP,
E1P8, E1P8-12, E1P8-13 and E1P8-21. Neither E1P8 nor its analogs
induced the release of vesicular contents.HI
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Fig. 3.% Leakage of POPG LUVs induced by HIV-1 FP, E1P8, E1P8-12, E1P8-13 and E1P8-21.3.2.2. Penetration kinetics
Membrane peptide afﬁnity can be determined by measuring the
exclusion pressure of insertion [32–34]. The exclusion pressure, πe,
which is the lipid monolayer surface pressure above which the peptide
does not penetrate into themonolayer, can be determined from the plot
of the initial lipid pressure (πi) as a function of surface pressure increase
(Δπ) by extrapolating the plot atΔπ=zero [35]. If amonolayer of phos-
pholipid is prepared at the air/water interface at a certain surface pres-
sure and a peptide is injected below the monolayer, the lipid ﬁlm
surface pressure would increase as peptide molecules bind to or insert
into the lipid monolayer at constant surface area [23,32]. The degree
of surface pressure increase depends on the type of lipid, initial ﬁlm
surface pressure, peptide surface activity, and concentration used.
Furthermore, given that the membrane lateral surface pressure has
been estimated to range between 25 and 35 mN m−1 [36,37], lower
values indicate a low level of interaction with the membrane.
The ability of E1P8 and its analogs E1P8-12, E1P8-13 and E1P8-21 to
insert into POPG anionic phospholipid monolayers spread through the
air–water interface was monitored by measuring variations in surface
pressure using different initial surface pressures of POPG, and byFig. 4. Surface pressure increase (Δπ) caused by HIV-1 FP, E1P8 and its analogues E1P8-12,
E1P8-13, E1P8-21 in monolayers of POPG in front of the lipid initial pressure (πi). Points *
indicate πe.of peptides from monolayer.
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pH 7.4). The selected concentration corresponds to the concentration
prior to saturation (0.38 μM).
A linear plot of Δπ versus πi was obtained for each peptide (Fig. 4).
The greater the πi the lower the incorporation of the peptide into the
monolayer because of the closer packing of the lipids at higher initial
surface pressure.
Table 2 shows the net charge of the peptides and the exclusion
pressure for E1P8, E1P8-12, E1P8-13 and E1P8-21; at this surface
pressure the POPG monolayer is in an expanded state, as described in
the section below, such that the peptides interact with the lipid through
hydrophobic interactions, while the absence of penetration is due to the
negative net charge of the peptides. The kinetic penetration of HIV-1 FP
was also studied. The HIV-1 FP πe, which was about 35 mN m−1,
demonstrates that this peptide penetrates better than E1P8 and its
analogs and interacts with the cellular membrane, presumably due to
the positive net charge of HIV-1 FP [29].3.2.3. Miscibility study
The interaction of E1P8 and its analogs with phospholipid mono-
layerswas also studied in a dynamic system.π-A compression isotherms
were obtained for pure POPG and changes induced by peptides either in
π-A isotherm shape or surface compression modulus were analyzed.
The surface compression modulus was calculated according to
Cs
−1 =−A(∂π/∂A)T, where A is the area per molecule at the indicated
surface pressure and π is the corresponding surface pressure. It can be
used to characterize the phase state of the monolayer (for liquid
expanded ﬁlms, the monolayer compressibility ranges from 12.5 to
50 mNm−1, while, for the liquid condensed phase, it ranges from 100
to 250 mN m−1) [33,38,39]. Deviations from the additivity rule were
also analyzed. These rule predicts that in a two-component system,
the area per molecule of the mixture at different mole fractions of
each component is a linear combination of the values of the area
per molecule for each component multiplied by its mole fraction
(A12id = X1A1 + X2A2, where A12id is the mean area per molecule of the
mixture of two components, A1 and A2 are the area per molecule of
the single components at the same surface pressure and X1 and X2 are
the mole fractions of components 1 and 2 in the mixed ﬁlm). This is
the case when there is either totally ideal mixing or complete immisci-
bility of the components. In the case that the area per molecule was
different from predicted by the additivity rule, the deviations may
be positives or negatives. That means the components interact via
repulsive or attractive forces respectively [40].
The capacity to form monolayers was studied by performing
compression isotherms. Fig. 5 shows the π-A compression isotherms
of pure monolayers (red line) of E1P8, E1P8-12, E1P8-13 and E1P8-21
and the lipid/peptidemixed ﬁlms at different molar fractions of compo-
nents. All formed stable monolayers at the interface. Like other similar
peptides [13,15], E1P8 and E1P8-12 exhibited a plateau at the collapse
region at 35 mN m−1 and 25 mN m−1 respectively, which could be
the result of the formation of a bilayer [41], or of molecular segments
being partially lifted from thewater surface [42], or of a change in orien-
tation of the molecules upon compression [43]. E1P8-13 and E1P8-21
monolayers result in a continuously rising isotherm with the collapse
pressure at 31 mNm−1 and 36 mN m−1 respectively.Table 2
Prediction of the isoelectric point, the net charge at pH 7.4 and the exclusion pressure (πe)
for HIV-1 FP, E1P8 and its derivatives E1P8-12, E1P8-13 and E1P8-21.
Isoelectric point Net charge at pH 7.4 Πe
HIV-1 FP 11.04 1 35
E1P8 2.94 −3.1 17
E1P8-12 2.94 −3 13
E1P8-13 2.94 −3.1 10
E1P8-21 4.04 −1.1 19The isotherm recorded for pure POPG (black line) showed a monot-
onous increase in surface pressure until collapse at about 42 mN m−1,
which is consistent with data already published; it was noted that the
POPG monolayer remained in liquid phase throughout compression
(Fig. 5-a inset), as described in previous studies [15,44]. Fig. 5 also
shows the mixed lipid/E1 peptide monolayers. Fig. 5-a shows the
E1P8/POPG mixed ﬁlms at different mole fractions. As the amount of
E1P8 in the monolayer increased, the pure POPG monolayer expanded,
so the area per molecule and Cs−1 values shifted to larger and lower
values respectively, indicating an increase in membrane ﬂuidity. Plots
of area per molecule versus monolayer composition at different surface
pressures are shown in Fig. 6-a. These show a slight negative deviation
from the additivity rule (see below) at low peptide mole fractions
(between 0.2 and 0.4) and also slight positive deviations at peptide
mole fractions greater than 0.5. Similar changes were observed in the
case of E1P8-12/POPG mixed ﬁlms (Fig. 5-b), in which as the peptide
mole fraction increased the area per molecule values also increased
and the Cs−1 decreased, making the membrane more compressible.
Plots of area per molecule in different mixtures (Fig. 6-b) showed
small deviations of ideal behavior mainly at low pressures. Fig. 5-d
presents the results obtained for E1P8-21; although it exhibited a simi-
lar general trend as E1P8 and E1P8-12 when mixed with POPG, the
expansion of pure POPGmonolayer was less apparent and themixtures
showed positive deviations from ideality (Fig. 6-d). Finally, in case of
E1P8-13 small negative deviations from the additivity rule at low sur-
face pressure were observed in the plot of area per molecule versus
monolayer composition (Fig. 6-c), while at higher surface pressure it
did not seem to modify the area per molecule of the pure POPG mono-
layer at any of the peptide mole fractions assayed, but like the other
peptides the Cs−1 values shifted to lower levels in comparison with
the POPG compression modulus.
Concerning collapse pressure, the πc of E1P8/POPG mixed mono-
layers shifted to slightly lower values as the peptide mole fraction
increased. Pure POPG and pure E1P8 peptide had a similar πc and only
when xE1P8 N 0.6 did the pseudoplateau appear. In the case of E1P8
derivatives/POPG binary mixtures, mixed ﬁlms exhibited a gradual
decrease in πc as the xpeptide increased. These results are better illustrated
by Cs−1 analyses (insets of Fig. 5-b, c and d), where the shift in the
maximum Cs−1 to lower values can be seen. In the case of E1P8-12
the shift in the Cs−1 minimum indicating the pressure at which the
pseudoplateau appeared is visible along with a second maximum, indi-
cating that E1P8-12 was probably squeezed out of the monolayer upon
compression, as when a binary mixture comprises components with
different collapse pressures, the resulting isotherm usually exhibits a
plateau at a pressure corresponding to the lower πc of the more ﬂuid
component, and a second πc corresponding to that of the more rigid
component [45].
To gain a better insight into the interactions established between
POPGwith E1P8, E1P8-12, E1P8-13 and E1P8-21, the excess free energy
of mixing (GE) associated with the process was calculated using Eq. (1),
as described by Pagano et al. [46], whereNA is Avogadro's number, A12 is
the mean area per molecule in the mixed ﬁlm, A1 and A2 are the areas
per molecule in the pure ﬁlms, X1 and X2 are the molar fractions, and
π is the surface pressure (mN m−1).
GE ¼ NA
Z
π→0
π
A12dπ− X1
Z
π→0
π
A1dπ þ X2
Z
π→0
π
A2dπ
  
ð1Þ
Table 3 shows the results obtained. The positive values indicate that
the process of mixing is not thermodynamically favored and therefore
repulsive interactions prevail in the mixtures in comparison with the
pure monolayers while negative values indicated that the lipid–peptide
interaction are greater than for pure components so, in this case, the
process of mixing are favored. In general, low values of |GE| were
observed, all of them lower than the product of RT (2477,5 J mol−1),
so according to Gaines et al. [47], the deviations from the additivity
Fig. 5. Surface pressure-mean area per molecule (π-A) compression isotherms for POPG and (a) E1P8, (b) E1P8-12, (c) E1P8-13 and (d) E1P8-21 spread on a Hepes subphase (pH 7.4).
Inset: Plots of surface compression modulus (Cs−1) as a function of the surface pressure.
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considered totally ideal or not.
3.2.4. Fluorescence microscopy
To analyze the effect of the peptides on the lipid phase-transition,
the structure of lipid monolayers at different surface pressures was
studied by ﬂuorescence microscopy (FM). As POPG remains in an
expanded state during monolayer compression until collapse occurs, a
saturated form of PG, DPPG, was used. DPPG has a clear phase-
transition from an expanded-liquid to a condensed-liquid state, so the
effect of our peptides on this phase transition could be analyzed by
transferring the monolayer at variable pressure onto glass cover-slips.
Fig. 7 shows the isotherms of DPPG in the absence or presence of 5
mol% of HIV-1 FP, E1P8, E1P8-12, E1P8-13 and E1P8-21. As in the case
of POPG, all peptides caused an expansion of the DPPG isotherm to
higher areas per molecule, indicating that the peptide was occupying
space in the interphase or perturbing the lipid packing. In the presence
of HIV-1 FP, the isotherm was similar to that of the monolayer contain-
ing only DPPG, with a change in slope close to 30 mNm−1 that was not
observed in the isotherm of DPPG. At lower pressures the shape of the
isotherm presented a plateau associated with the liquid-condensed to
liquid-expanded (LC-LE) phase transition of the phospholipid, centered
approximately at 5 mNm−1, 2 mNm−1 above the transition plateau of
DPPG alone [14], according to Cs−1 values (Fig. 7-inset).
The behavior of E1P8 and its analogs in DPPGmonolayers wasmore
variable. First, a change in the slope of the isothermswas visible at pres-
sures ranging from ~35 mN m−1 for E1P8-12 to over 45 mN m−1 for
isotherms containing E1P8-21. This change in the slope of the isotherm
during compression could be associatedwith changes in the orientation
of the peptides in the monolayer or even with partial exclusion of the
peptides from the lipid monolayer at higher pressures [48,49]. At
lower surface pressures, the monolayers prepared in the presence of
E1P8, E1P8-12 and E1P8-21 presented isotherms with a behavior
comparable to that of DPPG, appearing to alter the packing rearrange-
ment of DPPG along the phase transition from the LC to LE phases to a
lesser extent than HIV-1 FP. However, the DPPG isotherm prepared
in the presence of E1P8-13 showed an apparent shift in the phaseFig. 6. Plots of area permolecule for E1P8 (a), E1P8-12 (b), E1P8-13 (c) and E1P8-21 (d) as func
25 mN m−1 (□) surface pressures for pure and mixed monolayers of POPG.transition plateau at higher surface pressures (~10mNm−1) indicating
a larger effect on the packaging-rearrangement of DPPG molecules,
during the phase transition of the lipid than the other two E1P8 analogs.
This delay in the phase transition of DPPGmonolayer in the presence of
E1P8-13 can be conﬁrmed with Cs−1 values (Fig. 7-inset).
To further characterize the effect of the peptides on the lateral phase
transition ofDPPG,monolayerswere prepared in the presence of 1mol%
of the ﬂuorescent dye NBD-PC and were transferred to glass cover slips.
The phase transition was visible via ﬂuorescence microscopy (FM) as
the appearance of dark domains of condensed phase at the interface
that excluded the ﬂuorescent dye. These condensed domains grew in
size until thephase transitionwas complete and they almost completely
covered the interface, restricting the ﬂuorescent probe to smaller
regions surrounding the LC phase (Fig. 8). Monolayers containing
DPPG alone showed a phase transition from LC to LE at 25 °C starting
at very low surface pressures of less than 1 mN m−1, and ending
above 10 mNm−1.
The addition of the HIV-1 FP peptide to DPPG monolayers induced
two clear effects. On the one hand, HIV-1 FP disturbed the lateral
phase transition of the lipid, producing larger and more branched
domains. In addition, when compared with DPPG images taken at
similar pressures, the monolayers containing 5% HIV-1 FP needed to
be compressed to higher pressures to complete the transition. While
DPPG images showed that almost the entire surface was in the LC
phase at 20.4 mN m−1, the monolayers containing 5% HIV-1 FP still
showed well-deﬁned domains at 21 mN m−1 surrounded by regions
that remained in the liquid-expanded phase. HIV-1 FP could thus inter-
act preferentiallywith the expandedphase of DPPG, preventing the nor-
mal growth of LC domains and leading to the formation of branched
domains [50]. The heterogeneity in the LE regions observable at rela-
tively low surface pressures (Fig. 8, at 4 mN m−1) could be consistent
with the preferential accumulation of HIV-1 FP in this phase. At higher
pressures (Fig. 8, at 21 mN m−1) the presence of smaller domains in
the LE phase could be due to the formation of new LC regions of DPPG,
or even to the lateral segregation of the peptide from the LE phase [14].
When the effect of E1P8 and analog peptides on the phase transition
was analyzed, a lesser inﬂuence on the DPPG transition phase wastion of the peptidemole fractions at 5mNm−1 (■), 10mNm−1 (○), 20mNm−1 (●) and
Table 3
The excess free energy of mixing (GE) (J mol−1) in mixed monolayers of E1P8, E1P8-12,
E1P8-13, E1P8-21 and POPG at surface pressures 5 and 25 mNm−1.
GE (J mol−1)
5 mN m−1 25 mN m−1
E1P8 0.1 666.3 960.1
0.2 953.1 1109,6
0.4 65.6 215,5
0.6 −292.0 844.8
E1P8-12 0.1 137.3 −41.9
0.2 136.1 −1016.7
0.4 123.5 −2329.7
0.6 13.9 −1403.4
E1P8-13 0.1 −52.3 −201.4
0.2 −40.2 −327.5
0.4 −411.7 −544.8
0.6 −10.5 −386.3
E1P8-21 0.1 51.3 393.9
0.2 5.5 791.4
0.4 13.5 499.3
0.6 37.7 306.6
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domain compared with DPPG monolayers or even with DPPG mono-
layers containing the HIV-1 FP peptide. However, an apparent increase
in the number of domains per frame maintained the average packing
of the monolayer similar to that observed in the DPPG monolayers, if
it is compared with that caused by HIV-1 FP. This behavior could be
explained in terms of amore superﬁcial interaction between these pep-
tides, altering themanner in which the phase transition takes place and
thus producing a larger number of nucleation sites for the formation of
condensed domains but altering the overall process to a lesser extent
[20,48,49]. In the case of E1P8-12, besides the above mentioned effects,
a signiﬁcant change in the geometry of the domains was observed. On
the other hand, E1P8-13 also produced a clear effect on the total
condensed phase at low pressures (see Fig. 9, at 4.3 mN m−1) and led
to the formation of two different green levels in the expanded liquid
phase, as observed with HIV-1 FP. This result is also consistent with
the observed effect of the peptide on the isotherm cited above. TheseFig. 7. Surface pressure–mean area per molecule plot for DPPG, DPPG + 5% of HIV-1 FP, DPPG
Inset: Plots of surface compression modulus (Cs−1) as a function of the surface pressure.differences could be explained in terms of a better interaction between
E1P8-12 and E1P8-13, with the hydrophobic acyl chains of DPPG in the
monolayer altering the packing rearrangement of the acyl chains of the
phospholipid to a greater extent than E1P8 and E1P8-21. However, and
in contrast to the behavior of HIV-1 FP, the level of condensation in the
monolayer at higher pressures in the presence of E1P8-13was similar to
that observed in thepresence of E1P8, E1P8-12or E1P8-21. Thesewould
indicate that at these pressures, at which most of the phospholipid is in
the condensed phase, the lateral pressure could overcome the possible
effect of the substitution of a single amino acid in the sequence of the
peptides, producing a behavior and perhaps an interfacial rearrange-
ment comparable to that of E1P8 and its analogs.
3.3. E1 peptides–HIV-1 FP interactions
3.3.1. Additivity rule
In order to prove that E1P8 peptide and its analogs interact with
HIV-1 FP, in addition to the π-A compression isotherms for POPG/E1
peptide mixtures, the π-A compression isotherms of mixtures of
POPG/HIV-1 FP and POPG/HIV-1FP + E1 peptides (2:1) were obtained
(SupplementaryMaterial: Fig. S1). Itmust be pointed out that “peptide”
means any of the peptide studied or mixtures of HIV-1 FP/E1 peptide
(2:1). In this case each HIV-1 FP/E1 peptide (2:1) mixture is considered
as one component.
The mutual interaction (attractive or repulsive) between POPG and
peptide monolayers can be analyzed by examining whether the varia-
tion in area per molecule with the peptide mole fraction satisﬁes the
additivity rule. Fig. 10 shows the area per molecule versus Xpeptide
plots, at 10 mN m−1 surface pressure, for E1P8 (Fig. 10-a), E1P8-12
(Fig. 10-b), E1P8-13 (Fig. 10-c) and E1P8-21 (Fig. 10-d). Each plot
shows a comparison between the experimental area and the estimated
area based on idealmixing (indicated by dashed lines) for each case. For
the POPG/HIV-1 FP system (●), the experimental values indicated a
small positive deviation with a maximum at XHIV-1 FP = 0.2 and 0.6.
This implies the presence of a weak repulsive interaction between
POPG and HIV-1 FP at low surface pressure. In the case of E1P8,
E1P8-12 and E1P8-21, as indicated above, for Xpeptide ranging from 0.2+ 5% of E1P8, DPPG + 5% of E1P8-12, DPPG + 5% of E1P8-13 and DPPG + 5% of E1P8-2.
2.0 mN/m 4.1 mN/m 9.0 mN/m 20.4 mN/m 
2.6 mN/m 4.0 mN/m 9.3 mN/m 21.0 mN/m 5% FP
DPPG
Fig. 8. FM images from DPPG monolayers with or without 5% of HIV-1 FP. Images were taken at positions matching that indicate surface pressure from LB ﬁlms transferred during
continuous compression. Image size: 129.5 μm × 99.8 μm.
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than for HIV-1 FP. At Xpeptide of b0.2 and N0.6 the behavior is almost
ideal. E1P8-13 follows the additivity rule as shown in Fig. 10-c (■).
Finally, when a system of POPG and a mixture of HIV1-FP: E1 peptide
(2:1) (▲) (as indicated above the mixture of peptides is considered as
one component) was compressed slight negative deviations were
observed for E1P8 between XE1P8=0.1 and 0.4,with positive deviations
at XE1P8 N 0.4. For the E1P8-12 and E1P8-21 systems, the experimental
values were consistent with the theoretical values at all mole fractions.
Although the deviations from ideality were weak, it is interesting to
analyze the relative deviations caused by HIV-1 FP, and the HIV-1 FP/E1
peptide (2:1) mixtures. Fig. 11 shows the area per molecule versus
surface pressure at Xpeptide = 0.2. HIV-1 FP produced the largest POPG
expansionmonolayer indicating an interaction, according to the leakage
results. When the E1 peptides were added, the expansion was reduced
by half in the case of E1P8-12 and E1P8-13 and completely in the case of2.6 mN/m 4.4 mN/m5% E1P8
2.5 mN/m 4.5 mN/m5% E1P8-12
2.6 mN/m 4.3 mN/m5% E1P8-13
2.0 mN/m 4.3 mN/m5% E1P8-21
Fig. 9. FM images fromDPPGmonolayerswith orwithout 5% of E1P8, E1P8-12, E1P8-13 and E1P
transferred during continuous compression. Image size: 129.5 μm × 99.8 μm.E1P8 and E1P8-21. So, it seems that HIV-1 FP and the E1P8 analogs
interact to some extent, and that to explain the changes observed at
the membrane level the peptide/peptide interaction must be taken
into consideration.
3.3.2. Fluorescence microscopy
The effects of GBV-C E1P8 peptide and its analogs on the interaction
between HIV-1 FP and DPPG were analyzed by performing Langmuir–
Blodgett monolayer studies.
Fig. 12 shows the isotherms of DPPG alone and in the presence of 5
mol% of HIV-1 FP and different mixtures of HIV-1 FP/E1P8 derivative
peptides (1:2 mol/mol). In all cases, the isotherm is shifted to even
larger areas than that observed for any of the separate peptides. This
behavior could indicate a dramatic change how peptides, HIV-1 FP
and/or E1P8 analogs interact with each other or with DPPG in the
interface. Only the HIV-1 FP/E1P8 mixture showed similar areas per9.9 mN/m 19.4 mN/m
9.9 mN/m 20.6 mN/m
9.3 mN/m 16.6 mN/m
9.0 mN/m 16.6 mN/m
8-21. Imageswere taken at positionsmatching that indicate surface pressure from LB ﬁlms
Fig. 10. Plots of area–Xpeptide for mixtures of POPG–peptide at 10 mNm−1 surface pressure. a: E1P8 (■), HIV-1 FP (●), E1P8/HIV-1 FP (2:1) (▲); b: E1P8-12 (■), HIV-1 FP (●) and
E1P8-12/HIV-1 FP (2:1) (▲); c: E1P8-13 (■), HIV-1 FP (●), E1P8-13/HIV-1 FP (2:1) (▲); d: E1P8-21 (■), HIV-1 FP (●), E1P8/HIV-1 FP (2:1) (▲).
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separate peptides. None of the mixtures showed signiﬁcant differences
in the shape of the isotherm at pressures close to the phase transition of
DPPG with respect to the lipid alone, as it can be seen in Fig. 12-inset.
To further characterize the effect of the mixture of peptides on the
lateral phase transition of DPPG, the monolayers containing 1 mol% of
the ﬂuorescent dye NBD-PC were observed by FM, with the appearance
of dark domains of condensed phase at the interface that excluded the
ﬂuorescent dye. Fig. 13 shows images of the effect produced by the
different mixtures in DPPG monolayers. Surprisingly, the behavior of
the three peptides was comparable for the four combinations. All of
them seemed to cancel the clear effect of HIV-1 FP on the phase transi-
tion of DPPG, showing domains with shapes and sizes similar to that
observed in DPPG monolayers. The presence of HIV-1 FP also altered
the behavior of EP8-12 and E1P8-13. When these peptides were
added to the monolayer together with HIV-1 FP, the images obtained
also showed domains with geometry and distribution similar to DPPG
alone, in contrast with the shapes and the distribution observed when
both peptides were included independently in the interfacial monolay-
er. Although the behavior observed for the different peptide combina-
tions cannot be explained in terms of the total exclusion of HIV-1 FP
from the monolayer, it is possible that the simultaneous presence of0 10 20
0.0
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Fig. 11.Meanmolecular area increase in front of surface pressure increase ofmixture of POPGw
at molar fraction of peptides 0.2.HIV-1 FP and the peptides derived from E1P8 could produce a change
as HIV-1 FP when interacts with the monolayer, possibly from a rela-
tively deep character to a more peripheral disposition. The same effect
could make E1P8-12 and E1P8-13 in a comparable way to E1P8 and
E1P8-21 in the presence of HIV-1 FP.3.3.3. AFM imaging
To gain insight in the molecular organization of the interaction
between lipid monolayer and the peptides studied we carry out AFM
observations at two surface pressures. In this case, as indicated above,
a DPPC/DPPG (2:1) mixture was used as a model membrane.
Fig. 14 shows results of DPPC/DPPG (2:1) and DPPC/DPPG
(2:1)/peptides LB ﬁlms transferred from air-water interface on mica
substrate at 6 mN m−1 where, as previously reported [51,52], at room
temperature DPPC and DPPG isotherms are characterized by a shoulder
where LC and LE coexist. This is the case for DPPC/DPPG (2:1)monolayer
at 6 mN m−1.
The morphology of DPPC/DPPG (2:1) LB ﬁlm is shown in Fig. 14-A
(5 μm × 5 μm) and Fig. 14-a (1 μm × 1 μm), it can be seen irregular
LC lipid domains (bright areas) and LE regions (dark areas). In
Fig. 14-a it is possible to see themica substrate because of imperfections30
HIV-1 FP
E1P8/HIV-1 FP
E1P8-12/HIV-1 FP
E1P8-13/HIV-1 FP
E1P8-21/HIV-1 FP
POPG
N/m)
ith HIV-1 FP, E1P8/HIV-1 FP, E1P8-12/HIV-1 FP, E1P8-13/HIV-1 FP and E1P8-21/HIV-1 FP,
Fig. 12. Surface pressure-mean area permolecule (π-A) compression isotherms of DPPGwith 5% of HIV-1 FP/E1P8,HIV-1 FP/E1P8-12, HIV-1 FP/E1P8-13 andHIV-1 FP/E1P8-21. Inset: Plots
of surface compression modulus (Cs−1) as a function of the surface pressure.
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phases.
The presence of 5% E1 peptides (E1P8, E1P8-12, E1P8-13 and
E1P8-21) in the monolayer altered considerably the membrane
morphology. Consistent with the molecular hydrophobicity of the
peptides (see Fig. 1), all of them displayed the same abilities to change1.9 mN/m 4.6 mN/mE1P8/FP
2:1
2.0 mN/m 4.6 mN/mE1P8-12/FP
2:1
2.1 mN/m 4.0 mN/mE1P8-13/FP
2:1
2.1mN/m 4.1 mN/mE1P8-21/FP
2:1
Fig. 13. FM images fromDPPGmonolayerswith orwithout 5%ofHIV-1 FP/E1P8,HIV-1 FP/E1P8-
indicate surface pressure from LB ﬁlms transferred during continuous compression. Image sizelipid domains. Fig. 14-B and -b show the results obtained for the adsorp-
tion of E1P8 in the DPPC/DPPG (2:1) monolayer (images for E1P8
derivatives are supplied in the supplementary material Fig. S2, Fig S3
and Fig. S4). Accordingwith published results for amphipathic peptides
[53] it can be seen that E1P8 induces round big LC domains and
ﬁlaments in LE phase as a net that encloses a lower LC domains10.2 mN/m 22.8 mN/m
10.3 mN/m 23.0 mN/m
9.3 mN/m 17.0 mN/m
23.0 mN/m11.0 mN/m
12,HIV-1 FP/E1P8-13 andHIV-1 FP/E1P8-21. Imageswere taken at positionsmatching that
: 129.5 μm × 99.8 μm.
Fig. 14. AFM images for A: DPPC/DPPG (2:1), B: DPPC/DPPG (2:1) + E1P8 (5% mol),
C: DPPC/DPPG (2:1) + HIV-1 FP (5% mol), D: DPPC/DPPG (2:1) + E1P8 + HIV-1 FP
(2:1) (5% mol). Monolayers were transferred onto mica slides at 6 mN m−1. Data scale:
(A, B, C) 5 × 5 μm, (a, b, c) 1 × 1 μm. Z-scale: 4.0 nm, 4.0 nm, 1.3 nm and 5.8 nm for A,
B, C andD respectively and 3.0 nm, 4.0 nm, 0.8 nmand 2.0 nm for a, b, c and d respectively.
Fig. 15. AFM images for LB ﬁlm composed by DPPC/DPPG (2:1) + E1P8 (5% mol).
Monolayers were transferred from air–water interface onto mica slides at 6 mN m−1.
Fig. 16. AFM image for LB ﬁlm composed by DPPC/DPPG (2:1) + HIV-1 FP (5% mol).
Monolayers were transferred from air–water interface onto mica slides at 6 mN m−1.
Data scale 1 μm × 1 μm. Z-scale: 0.5 nm. White arrows indicate nanoholes induced by
HIV-1 FP peptide.
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differences in color tones. In this scale, dark brown is low and white is
high.
Fig. 14-C and -c show the effect of HIV-1 FP on DPPC/DPPG (2:1)
system.Also, in this case it can be seen howHIV-1 FP change LCdomains
but in a differentway that in case of E1 peptides probably due to the net
positive charge of HIV-1 FP. In this case hydrophobic interactions are
less favored because of the attractive electrostatic interactions between
HIV-1 FP and the anionic DPPG. The shape of LC domains dramatically
changes indicating that HIV-1 FP peptide interacts preferently at the
domain boundaries. On the other hand it can be seen the creation ofnanoholes (Figs. 14-c and 16 in detail) that are agree with the fusogenic
capacity of HIV-1 FP and results from leakage assay.
When HIV-1 FP and E1P8 are together in 2:1 ratio, AFM images
(Fig. 14-D and -d) showalso a LC-LEdomain regions and also aggregates
which are random distributed through the monolayer. In this case, the
LB morphology is exhibited in Fig. 14-D, it can be seen a big LC domain
with regular boundaries and no holes on it. Small LC domains are
distributed jointly with branched ﬁlaments within LE phase.
With compression DPPC/DPPG (2:1) LB ﬁlm sifts to more compact
and uniform topography (Fig. 17-A and -a, which were obtained at
30 mN m−1 surface pressure). In addition, it can be seen the changes
in the LB morphology at 30 mN m−1, when peptides were added:
E1P8 (5% mol) (Fig. 17-B and -b); HIV-1 FP (5% mol) (Fig. 17-C and -c)
and (E1P8 + HIV-1 FP (2:1)) (5% mol) (Fig. 17-D and -d).
In case of E1P8 only few white structures are displayed. It seems
that, with compression, E1P8 was excluded from the LB ﬁlm according
with its low capacity to penetrate anionic membranes while HIV-1 FP
adopts a good structured pattern that correlate with those obtained in
previous works on tilted peptides [54]. The presence of HIV-1 FP
provoked the appearance of elevated domains or nanorods at the
interface. Lins et al. [55] in their review “Relationships between the
Fig. 17. AFM images for A: DPPC/DPPG (2:1), B: DPPC/DPPG (2:1) + E1P8 (5% mol),
C: DPPC/DPPG (2:1) + HIV-1 FP (5% mol), D: DPPC/DPPG (2:1) + E1P8 + HIV-1 FP
(2:1) (5% mol). Monolayers were transferred onto mica slides at 30 mN m−1. Data
scale: (A, B, C) 5 × 5 μm, (a, b, c) 1 × 1 μm. Z-scale: 4.0 nm, 0.9 nm, 0.8 nm and 3.2 nm
for A, B, C and D respectively and 3.0 nm, 0.8 nm, 0.8 nm and 2.0 nm for a, b, c and d
respectively.
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interactions” suggested that these nanorods were presumably produced
by the self-association of reverse cylinders made of peptides and lipids,
due to the exposure of lipid tails; their association hence decreases the
contact with the aqueous medium.
Fig. 17-D exhibits the dramatic change observed inDPPC/DPPG (2:1)
membrane when a mixture of E1P8 + H HIV-1 FP (2:1) was added.
In this case, no nanorods appeared, small roundwhite spots are formed
(probably peptide clusters ormixed lipid–peptide patches). These spots
segregate out of LC domain. They show a tendency to associate. Vie et al.
in their work on detection of peptide–lipid interactions in mixedmonolayers [56], arrived to the conclusion that when the lipids are in
the LC state (DPPC and DPPG), the general features of the AFM images
reveal the existence of domains that are round for DPPG. According
with this, it is possible to hypothesize that the E1P8 and HIV-1 FP ﬁrst
interact themselves which allow a conformational change that favours
the interaction mainly with DPPG. The results demonstrate E1P8 avoid
the action of HIV-1 FP at membrane level. E1P8 and HIV-1 FP peptides
form compacted LB ﬁlms (Fig. 18-A and -a for E1P8 peptide and
Fig. 18-B and -b for HIV-1 FP) (white patches in Fig. 18-A are due to
artifacts during the transfer). Images in Fig. 18-C and -c show the
morphology of the LB ﬁlm composed by E1P8 + HIV-1 FP (2:1), two
peptides interact and arrange at the air-water interface yielding a circu-
lar structures different that those of E1PB or HIV-1 FP formedwhen they
are alone at the interface. Similar round structures were found for
others GBV-C peptides which also demonstrate their capacity to inhibit
HIV-1 FP in vitro and in vivo [29].
3.3.4. Hemolysis
We compared the parent peptide and its derivative peptides
(E1P8-12, E1P8-13 and E1P8-21)with regard to their capacity to inhibit
the hemolytic activity of HIV-1 FP in rabbit red blood cells.
It has previously been shown [57] that the incubation of erythro-
cytes with highly hydrophobic, synthetic HIV-1 FP usually results in
signiﬁcant hemolysis.
HIV-1 FP-induced hemolysis was measured in the absence and
presence of E1P8, E1P8-12, E1P8-13 and E1P8-21 peptides at different
concentrations (10, 100 and 100 μM). The maximum level of HIV-1
FP-induced hemolysis (100%) is reported relative to that measured in
the absence of these peptides and represents the average of three
measurements.
Neither peptides nor PBS alone induced hemolysis (data not shown).
Each peptide clearly inhibitedHIV-1 FPhemolytic activity (Fig. 19),with
hemolysis decreasing as their concentration increased. The parent
peptide had a higher inhibitory effect on HIV-1 FP-induced hemolysis
than its derivatives. At a molar ratio of 1:0.1 HIV-1 FP: E1 peptide
(10 μM of E1P8 and its analogs), E1P8 inhibited about 80% of HIV-1 FP
hemolysis, while E1P8-12 and E1P8-21 reduced HIV-1 FP hemolytic
activity by around 60%, and E1P8-13 by only about 20%. The HIV-1 FP
inhibitory activity of each peptide increased as their concentration
increased, with total inhibition at 100 μM.
4. Conclusion
The present work offers a biophysical study of the dependence of
E1P8 activity on its primary structure and its effect on HIV-1 FP action
at membrane level.
Three analogs of GBV-C E1P8, in which we had replaced C34 and L35
of the peptide sequence with A and E24 with R, were selected. These
modiﬁcations apparently enhance the anti-HIV-1 FP activity of E1P8.
In fact, these GBV-C E1P8 derivatives showed an increased capacity to
inhibit the leakage of POPG vesicles induced by HIV-1 FP with respect
to the parent peptide [18].
The adsorption kinetics of peptides showed that the selected analogs
present similar surface properties to the parent peptide, probably due to
same hydrophobic proﬁle of the peptides. The charge does not seem to
be signiﬁcant at this point as demonstrated by E1P8-21, in which we
replaced a negative amino acid (glutamic acid) with a positive residue
(arginine), which had the same activity as other peptides with a higher
net negative charge. The leakage and penetration kinetics results indi-
cate that the low interaction of the four peptides with anionic lipid is
probably due to the net negative charge of the peptides and its distribu-
tion on the primary sequence, which precludes a major lipid/peptide
interaction through the hydrophobic chains of the phospholipid. E1P8
and its analogs do not cause leakage and exhibit low πe values, ranging
between 10 and 19 mN m−1, which conﬁrms their inability to
penetrate biological membranes.
Fig. 18.AFM images for A: E1P8 GBV-C peptidemonolayer, B: HIV-1 FPmonolayer, C:monolayer of a mixture of E1P8+ HIV-1 FP (2:1). All monolayerswere transferred onmica slides at
6mNm−1. Data scale: (A, B, C) 5 μm×5 μm, (a, b, c): 1 μm×1 μm. Z-scale: 1.0 nm, 3.0 nm and 4.0 nm for A, B and C respectively and 2.0 nm, 4.0 nm and 4.0 nm for a, b, and c respectively.
405R. Galatola et al. / Biochimica et Biophysica Acta 1848 (2015) 392–407Themiscibility of peptide/lipid binarymonolayers was systematical-
ly investigated using compression isotherms and morphological
techniques (FM). The variations in collapse pressure and area per
molecule values suggest that some degree of interaction because the
presence of peptides leads to the expansion of the POPG monolayers,
except in the case of E1P8-13, and a gradual change in πc. These changes
are likely due to the different disposition and orientation of peptides
during compression and not to hydrophobic interactions. These facts
together with deviations in the additivity rule and GE values allow one
to hypothesize about the partial or total immiscibility of lipid/peptide
mixtures.
The results regarding HIV-1 FP/POPG and (HIV-1 FP/E1 peptides)/
POPG miscibility clearly indicate a certain degree of inhibition of
HIV-1 FP at the membrane level, reﬂecting the result obtained in a
leakage assay [18].FM images provide supporting morphological information on the
binary system obtained with HIV-1 FP (5% mol) or E1 peptides
(5% mol) and DPPG as the lipid component. HIV-1 FP (5%) modify LC
boundaries as also demonstrated at molecular level by AFM. In turn, E1
peptides caused a reduction in size of LC domains without modify the
LC/LE ratio probably due to a more superﬁcial interaction of E1 peptides
with DPPGmembrane or to themore afﬁnity of them for the LE phase as
AFM revealed. FM images frommixtures of E1 peptides+HIV-1 FP (2:1)
with DPPG showed domainswith a geometry and distribution similar to
lipid alone; it seems that E1 peptides avoid the HIV-1 FP effect at the
membrane. These ﬁndings were also corroborated by AFM.
In absence of the lipid, AFM images of mixtures of E1P8 and HIV-1
FP, showed the formation of a new structure indicating the interaction
between two peptides. This fact allows hypothesize that the E1P8
avoid the HIV-1 FP effect due to their mutual interaction.
Fig. 19. % Hemolysis induced by HIV-1 FP in presence of E1P8, E1P8-12, E1P8-13 and
E1P8-21 at increase concentration of E1P8 peptides.
406 R. Galatola et al. / Biochimica et Biophysica Acta 1848 (2015) 392–407These resultswere corroborated by the hemolysis study, inwhich all
peptides inhibited the hemolytic effect of HIV-1 FP, although the extent
of inhibitionwasdependent onpeptide concentration. Thebest behavior
in this case was shown by the E1P8 parent peptide, which drastically
affected the capacity of HIV-1 FP for hemolysis, decreasing it by more
than 80% at 10 μM. The combined results indicate that the changes in
the primary structure of E1P8 (C34, L35 and E24) do not appear to affect
its surface or hydrophobic properties, but change its behavior at the
membrane level, with the expansion of the POPGmonolayer becoming
negligible in the case of E1P8-13 (L35). The combined effect of HIV-1 FP
and the E1 peptides also supported this hypothesis, as mixtures of
HIV-1 FP + E1P8-21 (E24) and HIV-1 FP + E1P8 did not alter the area
per molecule values of POPG. In view of these facts, along with the
hemolysis results, it is rational to conclude that the replacement of
residues did not improve the anti HIV-1 FP activity of E1P8. Future
efforts to develop new forms of E1P8 peptide should bear this in
mind. Our current research is now focusing on the design of new E1P8
derivatives in which the primary structure remains unaltered, for
example, by creating a cyclic peptide through a disulﬁde link between
two cysteines.
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